Coronary Syndromes: Clinical Research and Personalized Medicine
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".
Deadline for manuscript submissions: 25 November 2024 | Viewed by 713
Special Issue Editors
2. Serviço de Cardiologia, Departamento de Coração e Vasos, CHULN Hospital de Santa Maria, Av Prof. Egas Moniz, 1649-028 Lisbon, Portuga
Interests: interventional cardiology; cardio-oncology; coronary artery disease; artificial intelligence applied to medicine
2. Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
3. Centro de Estudos de Medicina Baseada na Evidência (CEMBE, Evidence Based Medicine Centre), Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
4. Serviço de Cardiologia, Departamento de Coração e Vasos, CHULN Hospital de Santa Maria, Av Prof. Egas Moniz, 1649-028 Lisbon, Portugal
Interests: antithrombotic drugs; safety of cardiovascular drugs; cardiovascular effects of non-cardiovascular drugs; clinical trials; big data use; systematic reviews and meta-analysis; outcomes research
Special Issue Information
Dear Colleagues,
Coronary artery disease is perhaps the field of cardiology with the longest and largest body of research as it remains the leading form of heart disease and one of the leading causes of death globally. Notwithstanding, many issues regarding its approach remain under debate, especially regarding medical and interventional/surgical therapy.
On the issue of revascularization, large RCTs regarding chronic coronary syndromes, published within the past few years, challenged the invasive approach for these patients. However, they are not without significant caveats, and thus many patients may still benefit from revascularization. Furthermore, as evidence for techniques in physiology and imaging (both invasive and non-invasive) grows, several strategies for diagnosing coronary artery disease and individualizing revascularization are likely to surface in the coming years, both for acute and coronary syndromes. Thus, it has perhaps never been more significant to adopt a personalized approach regarding whom, when, and how to apply revascularization.
Medical therapy has also seen very significant developments. Strategies regarding antithrombotic (particularly antiplatelet) therapy have become increasingly varied, with many trials testing varying degrees of therapy duration/intensity, as well as different combinations of drugs. Testing for antiplatelet inhibition or genetic profiling of patients is another issue of significant debate. Moreover, the issue of cardiovascular risk factor control strategies, particularly for dyslipidemia, has seen many recent developments, and new pharmacological options are quickly becoming available, such as newer PCSK9 inhibitors or bempedoic acid. Once more, a growing trend for a personalized approach is growing ever stronger, further fuelled by the seemingly inevitable rise of artificial intelligence, which has been taking the world by storm, with the medicine sector being no exception.
This Special Issue will focus on coronary artery disease research, primarily from a clinical standpoint, while addressing the issue of personalizing its approach. Papers may focus on specific subpopulations, via diagnostic or therapeutic strategies, regarding all aspects of coronary artery disease (acute or chronic, epicardial, or non-epicardial). Original research and review articles are particularly sought after, but we also welcome communication papers or systematic reviews.
Dr. Miguel Nobre Menezes
Dr. Daniel Caldeira
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- coronary artery disease
- percutaneous coronary intervention
- coronary artery bypass surgery
- antiplatelet therapy
- new and upcoming drugs for dyslipidemia
- medical therapy for chronic and acute coronary syndromes
- invasive and non-invasive diagnostic modalities
- non-epicardial coronary artery disease
- coronary artery disease in special populations (elderly, cancer, etc.)
- cardiovascular risk factors
